Common drug reverses the devastating gum disease

Scientists have discovered that a drug already approved for the treatment of hardening and psoriasis shows a remarkable promise in the fight against periodontitis, one of the main causes of tooth loss worldwide.

Researchers at Wenzhou Medical University found that Dimethyl Fumadium (DMF) significantly reduced bone loss and inflammation in experimental models of gum disease by improving cellular “cleansing” mechanisms and shifting it.

“The ability of the Dimethyl Foumari to refine the polarization of macrophages through mitophagia is a player who changes periodontal treatment,” said Dr. Shengbin Huang, the corresponding author of the study. “With the targeting of the mitochondrial protein TUFM, we have revealed a molecular switch that controls the inflammatory response to the gum tissue.

Periodontitis affects millions worldwide and occurs when simple gum inflammation progresses to destroy supporting structures around the teeth. Traditional treatments, which focus mainly on removing the bacterial plaque and antibiotic administration, often fail to stop the progression of the disease.

The discovery, published in international Newspaper of oral scienceIt focuses on DMF’s double ability to protect mitochondria – cell forces – and alter the behavior of macrophages, significant immune cells that can either promote inflammation or facilitate healing.

In healthy gums, there is a balance between pre-inflammatory (M1) and treatment (M2). During periodontitis, this balance tips largely to the devastating cells M1. Researchers have shown that DMF helps to restore this balance by protecting a basic protein called TUFM that maintains cell health.

When TUFM was experimentally exhausted, DMF lost its protective results, confirming the crucial role of this protein in the success of treatment. The drug appears to function by preventing the degradation of TUFM in cells, allowing it to orchestrate a cellular cleansing process called mitophagia that removes damaged mitochondria.

What makes this discovery is particularly promising is that DMF has already been approved by FDA for other conditions, possibly accelerating its course for clinical use for periodontitis. Future applications may include local formulations that apply directly to the tissue affected by the gums to minimize any systematic side effects.

In addition to saving teeth, these findings could have a wider impact. Cell mechanisms targeted by DMF are common in many inflammatory diseases, indicating possible applications for situations such as rheumatoid arthritis or inflammatory bowel disease.

For patients with periodontitis, this study offers hope that treatment options may soon be extended beyond the limitations of current approaches. A drug that deals with the underlying immune imbalance, instead of combating bacteria, could convert the effects for this common but devastating oral disease.